LYB001

LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.^[1]^[2]^[3]^[4]

It was found to be safe and well tolerated.^[5]

References

^ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
^ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.
^ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
^ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.
^ Tang, Rong; Zeng, Ying; Zhou, Yu; Liang, Qi; Kang, Wei; Yang, Zhonghua; Zheng, Xiaoxiang; Zang, Xia; Pan, Hongxing; Jin, Jing; Zhu, Fengcai (2 May 2024). "Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study". Expert Review of Vaccines. 23 (1): 498–509. doi:10.1080/14760584.2024.2337051. PMID 38695310.

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.